One-Year Outcomes of 1 Dose Versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

Journal of Ophthalmology - Egypt
doi 10.1155/2019/7530458